Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

NCT05174585 is registered in ClinicalTrials.gov with Jacobio Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT05174585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05174585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Lead sponsor
Jacobio Pharmaceuticals Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
August 18, 2022
Completion date
May 9, 2025
Enrollment
21 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor